Chronic Lung Diseases Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Rethinking Idiopathic Pulmonary Fibrosis: Unmet Needs, Evolving Biology and the Future of Clinical Research

Life Science Spotlight

What Are the Key Considerations for Overcoming Challenges in IPF and Other Rare Respiratory Disease Clinical Trials?

December 11, 2025

Jascayd (Nerandomilast) Gains FDA Approval as First IPF Therapy in 10 Years

October 10, 2025

FDA Approves Brinsupri (Brensocatib), First Targeted Therapy for Non-Cystic Fibrosis Bronchiectasis

August 15, 2025

Overcoming IPF and Other Rare Respiratory Disease Clinical Trial Challenges

September 19, 2025

From Symptoms to Solutions: Enhancing Interstitial Lung Disease (ILD) Trials with Next-Gen Assessments

Clinical Trial News

Nerandomilast Achieves Positive Phase III Results in Progressive Pulmonary Fibrosis

February 12, 2025

IMVARIA’s FDA-Cleared ScreenDx Brings AI-Powered Screening to Interstitial Lung Disease

January 15, 2025

Alyftrek: Vertex Expands Cystic Fibrosis Treatment with Triple-Action Combo

January 6, 2025

Clinical Trial News

Deupirfenidone Could Perform Better Than Standard IPF Therapy

December 23, 2024

Namilumab Discontinued After Phase II Trial Failure for Pulmonary Sarcoidosis

December 6, 2024

Disrupting Cancer Cells on the Go: Novocure’s Optune Lua Device for Portable NSCLC Therapy

October 17, 2024

Nasal Delivery of mRNA Therapeutics: A Novel Approach to Drug Development for Asthma

October 1, 2024

Life Science Podcast

Pioneering mRNA Therapies for Lung Diseases

September 25, 2024

Rybrevant-Lazcluze Combo, First Chemotherapy-Free Option for Advanced NSCLC, Approved

August 27, 2024

Verona’s COPD Drug Ohtuvayre (ensifentrine) Gets FDA Nod

Next Page »